{"type":"trials","record":{"id":41918,"source_id":"clinicaltrials-gov","external_id":"NCT01940887","title":"A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy","brief_summary":"The objectives of this study are to evaluate the safety and efficacy of intravitreal administration of Fovista® administered in combination with either Avastin® or Eylea® compared to Avastin® or Eylea® monotherapy in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).","overall_status":"Terminated","phases":["PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"Ophthotech Corporation","enrollment":645,"countries":["United States","Argentina","Australia","Austria","Brazil","Canada","Colombia","Croatia","Czechia","Estonia","Finland","France","Germany","Hungary","Israel","Italy","Latvia","Norway","Poland","Portugal","Slovakia","Spain"],"start_date":"2014-05-01","completion_date":"2017-09-01","last_update_date":"2024-10-31","source_url":"https://clinicaltrials.gov/study/NCT01940887","editorial_summary":"A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":"Sham + bevacizumab or aflibercept","organization":"Astellas Pharma Inc","interventions":["E10030","bevacizumab or aflibercept","E10030 sham injection"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Mean Change in Visual Acuity (Measured at Baseline and at the Month 12 Visit) — 12 months"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":true},"controlled_terms":["Age-Related Macular Degeneration","E10030","bevacizumab or aflibercept","E10030 sham injection"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct01940887","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2014-05-01 to 2017-09-01","comparator":"Sham + bevacizumab or aflibercept","confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.891Z","intervention":["E10030","bevacizumab or aflibercept","E10030 sham injection"],"participants":645,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Mean Change in Visual Acuity (Measured at Baseline and at the Month 12 Visit) — 12 months"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41918","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}